The Patent Finder

Immunomodulatory Fusion Proteins

Epicentrx, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application 62/484,841, filed Apr 12, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 10,906,957Immunomodulatory Fusion Proteins
In force
 · High confidence
Epicentrx, Inc.In force
High confidence
US 12,054,530Immunomodulatory Fusion Proteins
In force
 · Low confidence
Epicentrx, Inc.In force
Low confidence
Application 18/772,025Immunomodulatory Fusion Proteins
Pending
Not granted
Epicentrx, Inc.PendingNot granted
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Epicentrx, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited